Study of the effects of Biperiden drug on reducing the desire to quit smoking

Study of the acute effects of Biperiden on nicotine cravings: double-blind, placebo-controlled study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

REBEC

Registry ID

RBR-7qtvbh3

Enrollment

Unknown

Registered

2025-04-17

Start date

2023-10-20

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco Use Disorder

Interventions

This is a two-arm, double-blind, randomized controlled clinical study. A total of 40 people who meet the eligibility criteria will be probabilistically allocated to one or another intervention group u

D27.505.519.625.120.200.500

Eligibility

Sex/Gender

Male

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with nicotine use disorder, according to DSM-5 criteria; who have intense compulsion, according to the Questionnaire of Smoking Urges-Brief (43 or more points); aged between 18 and 60 years; male and literate (with the ability to write and read Portuguese)

Exclusion criteria

Exclusion criteria: Present other psychiatric disorders (serious such as schizophrenia and bipolar mood disorder); severe disorder criteria when using other drugs or severe cognitive impairment

Design outcomes

Primary

Measure	Time frame
It is expected to observe a decrease in the compulsion to use nicotine and the number of cigarettes used per day, as well as changes in anxiety, depression and degree of dependence.	—

Secondary

Measure	Time frame
No secondary internships are expected.	—

Countries

Brazil

Contacts

Public ContactJosé Galduróz

Universidade Federal de São Paulo

galduroz@unifesp.br+55(11) 2149 0155

Outcome results

None listed

Source: REBEC (via WHO ICTRP)